Literature DB >> 9180898

Possible role of coexpression of CD9 with membrane-anchored heparin-binding EGF-like growth factor and amphiregulin in cultured human keratinocyte growth.

S Inui1, S Higashiyama, K Hashimoto, M Higashiyama, K Yoshikawa, N Taniguchi.   

Abstract

CD9 is a protein with 4 transmembrane domains, and functions as a cell surface antigen. We have previously reported that CD9 functions as an up-regulator of membrane-anchored heparin-binding EGF-like growth factor (proHB-EGF) activity, which is a potent mitogen as well as a soluble HB-EGF. Anti-CD9 antibodies can neutralize the juxtacrine activity of proHB-EGF when both CD9 and proHB-EGF are coexpressed. We demonstrated here: (1) the CD9 gene was transcribed and translated in the cultured human keratinocytes; (2) anti-CD9 antibody inhibited the approximately 50% growth of human keratinocytes in culture; (3) CD9 was coprecipitated with proHB-EGF and membrane-anchored amphiregulin (proAR), and (4) the transient coexpression of CD9 with proHB-EGF or proAR in mouse L cells up-regulated their juxtacrine growth factor activities. These results suggest that CD9 would make a heterodimer and/or trimer complex with proHB-EGF and proAR, and might cooperate with proHB-EGF and proAR for human keratinocyte growth in a juxtacrine manner.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9180898     DOI: 10.1002/(SICI)1097-4652(199706)171:3<291::AID-JCP7>3.0.CO;2-J

Source DB:  PubMed          Journal:  J Cell Physiol        ISSN: 0021-9541            Impact factor:   6.384


  18 in total

1.  The heparin-binding domain of HB-EGF mediates localization to sites of cell-cell contact and prevents HB-EGF proteolytic release.

Authors:  Robin N Prince; Eric R Schreiter; Peng Zou; H Steven Wiley; Alice Y Ting; Richard T Lee; Douglas A Lauffenburger
Journal:  J Cell Sci       Date:  2010-06-08       Impact factor: 5.285

Review 2.  Epidermal growth factor receptor mediates injury in rapidly progressive glomerular disease.

Authors:  Sabine Brandt; Peter R Mertens
Journal:  Int Urol Nephrol       Date:  2012-03-24       Impact factor: 2.370

Review 3.  Why is delta endocytosis required for effective activation of notch?

Authors:  Ajay Chitnis
Journal:  Dev Dyn       Date:  2006-04       Impact factor: 3.780

4.  Role of CD9 in proliferation and proangiogenic action of human adipose-derived mesenchymal stem cells.

Authors:  Yeon Jeong Kim; Ji Min Yu; Hye Joon Joo; Hoe Kyu Kim; Hyun Hwa Cho; Yong Chan Bae; Jin Sup Jung
Journal:  Pflugers Arch       Date:  2007-08-01       Impact factor: 3.657

5.  Expression of EGF-family receptors and amphiregulin in multiple myeloma. Amphiregulin is a growth factor for myeloma cells.

Authors:  Karène Mahtouk; Dirk Hose; Thierry Rème; John De Vos; Michel Jourdan; Jérôme Moreaux; Geneviève Fiol; Marc Raab; Eric Jourdan; Véronique Grau; Marion Moos; Hartmut Goldschmidt; Marion Baudard; Jean François Rossi; Friedrich W Cremer; Bernard Klein
Journal:  Oncogene       Date:  2005-05-12       Impact factor: 9.867

6.  The membrane-anchoring domain of epidermal growth factor receptor ligands dictates their ability to operate in juxtacrine mode.

Authors:  Jianying Dong; Lee K Opresko; William Chrisler; Galya Orr; Ryan D Quesenberry; Douglas A Lauffenburger; H Steven Wiley
Journal:  Mol Biol Cell       Date:  2005-04-13       Impact factor: 4.138

Review 7.  Novel CD9-targeted therapies in gastric cancer.

Authors:  Yoko Murayama; Kenji Oritani; Shusaku Tsutsui
Journal:  World J Gastroenterol       Date:  2015-03-21       Impact factor: 5.742

Review 8.  The role of the EGF family of ligands and receptors in renal development, physiology and pathophysiology.

Authors:  Fenghua Zeng; Amar B Singh; Raymond C Harris
Journal:  Exp Cell Res       Date:  2008-08-19       Impact factor: 3.905

Review 9.  Amphiregulin as a novel target for breast cancer therapy.

Authors:  Nicole E Willmarth; Stephen P Ethier
Journal:  J Mammary Gland Biol Neoplasia       Date:  2008-04-25       Impact factor: 2.673

Review 10.  Targeting of tetraspanin proteins--potential benefits and strategies.

Authors:  Martin E Hemler
Journal:  Nat Rev Drug Discov       Date:  2008-09       Impact factor: 84.694

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.